FDA Approves Treatment For Alzheimer's Disease
(MENAFN- Gulf Times) The US Food and Drug Administration (FDA) on Tuesday approved Kisunla (donanemab-azbt) injection, produced by Eli Lilly, for the treatment of Alzheimers disease is the third amyloid-targeting drug approved by the FDA since 2021, following two treatments Aduhelm and Leqembi slowed the cognitive and functional decline in patients with mild cognitive impairment by 35 percent over 18 months drug removes beta-amyloid that accumulates in the brains of patients with Alzheimer's disease estimated cost for a six-month course of the therapy is $12,522. A full year of treatment is protected to cost $32,000, according to Eli Lilly.
MENAFN03072024000067011011ID1108401818
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.